Click the “Start Activity” button to indicate you have reviewed the CME information for this activity.

Activity Speakers

Parameswaran Hari, MD, MRCP, MS
Armand Quick-William Stapp Professor of Hematology
Interim Chief Hematology and Oncology
Medical College of Wisconsin
Milwaukee, WI

Luciano J. Costa, MD, PhD
Associate Professor
Department of Medicine and Bone Marrow
Transplantation and Cell Therapy Program
University of Alabama, Birmingham
Birmingham, AL

Release date: May 16, 2018
Expiration date: May 16, 2019

Program Overview
The goal of this educational program is to improve the treatment of patients with multiple myeloma (MM) and non-hodgkin lymphoma (NHL) through the dissemination of information about stem cell transplantation and mobilization for autologous hematopoietic cell transplantation. The data for stem cell transplantation in MM is rapidly changing. The techniques of mobilization are still evolving. There is considerable debate regarding the timing and number of transplants for MM and the indications for transplant in NHL. The optimal use of transplant in the disease course and appropriate mobilization could drastically change the treatment of MM and NHL. This program serves as a medium to give physicians a chance to  recognize these changes.

Learning Objectives
The following items are the learning objectives in CME format for this program. Upon completion of this program, participants will be able to:

  1. Identify existing and emerging strategies for optimizing stem cell transplantation in MM and NHL
  2. Evaluate current data on stem cell mobilization in patients with MM and Hodgkin’s disease
  3. Determine the factors that affect and optimize the efficacy of stem cell mobilization


Target Audience
The intended audience for this activity is transplant specialists, oncologists, hematologists and other healthcare professionals involved in the treatment of patients with GVHD.

Needs Assessment
Hematopoietic stem cell transplantation (HSCT) is an important life prolonging or curative option for patients with hematologic malignancies such as MM and NHL. Despite promising data and continued recommendations from the National Comprehensive Cancer Center (NCCN) that state transplants should be considered in patients with symptomatic disease, studies from the United States suggest that transplants are only used in approximately 30% of MM patients. Understanding the role of transplants and the barriers affecting its ideal utilization is critical when attempting to influence wider use of transplants as a therapeutic option.

The mobilization of hematopoietic stem cells fails in approximately 20% of MM patients and in up to 40% of NHL patients. Poor mobilization can partially be attributed to certain clinical factors, but cannot often be predicted. Mobilization methods include hematopoietic growth factors (G-CSF and GM-CSF), alone (GF), or cytotoxic chemotherapy plus growth factor (CC+GF). However, studies are still investigating the optimal method for stem cell mobilization. Proponents of CC+GF believe that the chemotherapy agent helps long-term disease control and is associated with higher CD34+ yields. However, CC+GF mobilization is also associated with significant morbidity with increased risks of infection and hospitalization and increased cost. This program will discuss the new developments in the fields of autologous stem cell transplantation and mobilization that allow a wider range of patients to receive transplantation.

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and Carden Jennings Publishing. The Medical College of Wisconsin is accredited with commendation by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement
The Medical College of Wisconsin designates the live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in these activities. Hours of Participation for Allied Health Care Professionals: The Medical College of Wisconsin designates the live activity for up to 1.0 hours for continuing education for allied health professionals.

CJP Medical Communications Disclosure
The employees of CJP Medical Communications have no financial relationships to disclose.

Faculty and Planner Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:

James Ferrara, MD, DSc discloses that he has a GVHD biomarker patent from which he receives a royalty.

Motoko Koyama, MD, PhD has no relevant conflicts of interest to disclose.

Ernst Holler, MD, PhD discloses that he serves on the advisory board for Pharmacyclics. He also has received honoraria from Prime Oncology and Sanofi.

The educational content of this program has been peer reviewed by The Medical College of Wisconsin.

The Medical College of Wisconsin and Carden Jennings Publishing report the following relationship(s): No relevant financial relationships to disclose.

Signed disclosures are on file at The Medical College of Wisconsin.

Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

The material presented at or in any Medical College of Wisconsin or Carden Jennings Publishing Company, Ltd. continuing education activity does not necessarily reflect the views and opinions of Medical College of Wisconsin or Carden Jennings Publishing. Neither Medical College of Wisconsin or Carden Jennings Publishing, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the U.S. Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME and Support Information
This continuing medical education activity is provided by The Medical College of Wisconsin. Collaborative Partner: Carden Jennings Publishing.

This activity is supported by an educational grant from Sanofi Genzyme.

Click the “Start Activity” button to indicate you have reviewed the CME information for this activity.